Roberto Zatz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roberto Zatz has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Clarice Kazue Fujihara
Universidade de São Paulo Faculdade de Medicina Department of Clinical Medicine
6 shared publicationsDenise Maria Avancini Costa Malheiros
Universidade de São Paulo Faculdade de Medicina Department of Clinical Medicine
3 shared publicationsAna Lúcia Mattar
Universidade de São Paulo Faculdade de Medicina Department of Clinical Medicine
2 shared publications- Gilberto De Nucci
Department of Pharmacology, Faculty of Medical Sciences State University of Campinas (UNICAMP) Campinas Brazil
2 shared publications - Ana Carolina P Souza
Nephrology Service, University of Sao Paulo School of Medicine, São Paulo, SP, Brazil.
1 shared publication Ana L|[Uacute]|Cia Mattar
University of São Paulo
1 shared publication
Latest Publications
- Open Access
- 8 April 2015
- Published by Springer Nature in BMC Nephrology
- Vol. 16 (1) , 46
Is urinary density an adequate predictor of urinary osmolality?
Urinary density (UD) has been routinely used for decades as a surrogate marker for urine osmolality (Uosm). We asked if UD can accurately estimate Uosm both in healthy subjects and in different clinical scenarios of kidney disease. UD was assessed by refractometry. Uosm was measured by freezing point depression in spot urines obtained from healthy volunteers (N = 97) and in 319 inpatients with acute kidney injury (N = 95), primary glomerulophaties (N = 118) or chronic kidney disease (N = 106). UD and Uosm correlated in all groups (p < 0.05). However, a wide range of Uosm values was associated with each UD value. When UD was ≤ 1.010, 28.4% of samples had Uosm above 350 mOsm/kg. Conversely, in 61.6% of samples with UD above 1.020, Uosm was below 600 mOsm/kg. As expected, Uosm exhibited a strong relationship with serum creatinine (Screat), whereas a much weaker correlation was found between UD and Screat. We found that UD is not a substitute for Uosm. Although UD was significantly correlated with Uosm, the wide dispersion makes it impossible to use UD as a dependable clinical estimate of Uosm. Evaluation of the renal concentrating ability should be based on direct determination of Uosm.
- 8 April 2015
- Published by Springer Nature in BMC Nephrology
- Vol. 16 (1) , 46
Open AccessIs urinary density an adequate predictor of urinary osmolality?
Urinary density (UD) has been routinely used for decades as a surrogate marker for urine osmolality (Uosm). We asked if UD can accurately estimate Uosm both in healthy subjects and in different clinical scenarios of kidney disease. UD was assessed by refractometry. Uosm was measured by freezing point depression in spot urines obtained from healthy volunteers (N = 97) and in 319 inpatients with acute kidney injury (N = 95), primary glomerulophaties (N = 118) or chronic kidney disease (N = 106). UD and Uosm correlated in all groups (p < 0.05). However, a wide range of Uosm values was associated with each UD value. When UD was ≤ 1.010, 28.4% of samples had Uosm above 350 mOsm/kg. Conversely, in 61.6% of samples with UD above 1.020, Uosm was below 600 mOsm/kg. As expected, Uosm exhibited a strong relationship with serum creatinine (Screat), whereas a much weaker correlation was found between UD and Screat. We found that UD is not a substitute for Uosm. Although UD was significantly correlated with Uosm, the wide dispersion makes it impossible to use UD as a dependable clinical estimate of Uosm. Evaluation of the renal concentrating ability should be based on direct determination of Uosm.
- 1 January 2009
- Published by Elsevier in Kidney International
- Vol. 75 (1) , 72-79
Regression of glomerular injury by losartan in experimental diabetic nephropathy
- 1 January 2009
- Published by Elsevier in Kidney International
- Vol. 75 (1) , 72-79
Regression of glomerular injury by losartan in experimental diabetic nephropathy
- Open Access
- 16 March 2006
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Medicina
- Vol. 85 (1) , 28-29
Entrevista: Prof. Dr. Roberto Zatz
- 16 March 2006
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Medicina
- Vol. 85 (1) , 28-29
Open AccessEntrevista: Prof. Dr. Roberto Zatz
- Open Access
- 1 January 2006
- Published by Taylor & Francis in Renal Failure
- Vol. 28 (8) , 627-629
End-Stage Renal Failure and National Resources: The Brazilian Experience
Brazil is the fifth largest and the fifth most populous nation in the world. Its economy rivals Mexico as the strongest in Latin America and ranks among the 15 largest economies in the world. Despite these achievements, a substantial fraction of the Brazilian population still lives in poverty, and many still have limited access to medical assistance. There are currently about 380 patients on hemodialysis per million populations (pmp), approximately one third of the U.S. prevalence, suggesting that a large fraction of end-stage renal disease (ESRD) patients are not diagnosed and treated properly. In Brazil, access to renal replacement therapy (RRT), including renal transplantation, is universal, and the corresponding costs, including those of medications (immunosuppressors and treatment of ESRD complications), are covered by the Brazilian government. However, given the continuous growth of the ESRD population and of the costs incurred by RRT, the efficacy and reach of this system may be severely limited in years to come. In the current struggle against the ESRD epidemics, the Brazilian medical community and health authorities face a triple challenge: to limit the incidence of renal disease, slow or detain the progression of established chronic nephropathies, and ensure that access to quality RRT remains granted to all those who, despite all efforts, reach ESRD.
- 1 January 2006
- Published by Taylor & Francis in Renal Failure
- Vol. 28 (8) , 627-629
Open AccessEnd-Stage Renal Failure and National Resources: The Brazilian Experience
Brazil is the fifth largest and the fifth most populous nation in the world. Its economy rivals Mexico as the strongest in Latin America and ranks among the 15 largest economies in the world. Despite these achievements, a substantial fraction of the Brazilian population still lives in poverty, and many still have limited access to medical assistance. There are currently about 380 patients on hemodialysis per million populations (pmp), approximately one third of the U.S. prevalence, suggesting that a large fraction of end-stage renal disease (ESRD) patients are not diagnosed and treated properly. In Brazil, access to renal replacement therapy (RRT), including renal transplantation, is universal, and the corresponding costs, including those of medications (immunosuppressors and treatment of ESRD complications), are covered by the Brazilian government. However, given the continuous growth of the ESRD population and of the costs incurred by RRT, the efficacy and reach of this system may be severely limited in years to come. In the current struggle against the ESRD epidemics, the Brazilian medical community and health authorities face a triple challenge: to limit the incidence of renal disease, slow or detain the progression of established chronic nephropathies, and ensure that access to quality RRT remains granted to all those who, despite all efforts, reach ESRD.
- Open Access
- 1 May 2004
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 286 (5) , F945-F954
Renal expression of COX-2, ANG II, and AT1receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory
Chronic renal injury can be mediated by angiotensin II (ANG II) and prostanoids through hemodynamic and inflammatory mechanisms and attenuated by individual suppression of these mediators. In rats with ⅚ renal ablation (Nx), we investigated 1) the intrarenal distribution of COX-2, ANG II, and the AT1receptor (AT1R); 2) the renoprotective and antiinflammatory effects of an association between the AT1R blocker, losartan (Los), and the gastric sparing anti-inflammatory nitroflurbiprofen (NOF). Adult male Munich-Wistar rats underwent Nx or sham operation (S), remaining untreated for 30 days, after which renal structure was examined in 12 Nx rats (Nxpre). The remaining rats were followed during an additional 90 days, distributed among 4 treatment groups: NxV(vehicle), NxLos(Los), NxNOF(NOF), and NxLos/NOF(Los/NOF). Nxprerats exhibited marked albuminuria, hypertension, glomerulosclerosis, interstitial expansion, and macrophage infiltration, accompanied by abnormal glomerular, vascular, and interstitial COX-2 expression. ANG II appeared in interstitial cells, in contrast to S, in which ANG II was virtually confined to afferent arterioles. Intrarenal AT1R distribution shifted from mostly tubular in S to predominantly interstitial in Nxpre. All these changes were aggravated at 120 days and attenuated by Los and NOF monotherapies. Los/NOF treatment arrested renal structural injury and ANG II expression and reversed hypertension, albuminuria, and renal inflammation. In conclusion, abnormal expression of COX-2, ANG II, and AT1R may be key to development of renal injury in Nx. Concomitant COX-2 inhibition and AT1R blockade arrested renal injury and may represent a useful strategy in the treatment of chronic nephropathies.
- 1 May 2004
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 286 (5) , F945-F954
Open AccessRenal expression of COX-2, ANG II, and AT1receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory
Chronic renal injury can be mediated by angiotensin II (ANG II) and prostanoids through hemodynamic and inflammatory mechanisms and attenuated by individual suppression of these mediators. In rats with ⅚ renal ablation (Nx), we investigated 1) the intrarenal distribution of COX-2, ANG II, and the AT1receptor (AT1R); 2) the renoprotective and antiinflammatory effects of an association between the AT1R blocker, losartan (Los), and the gastric sparing anti-inflammatory nitroflurbiprofen (NOF). Adult male Munich-Wistar rats underwent Nx or sham operation (S), remaining untreated for 30 days, after which renal structure was examined in 12 Nx rats (Nxpre). The remaining rats were followed during an additional 90 days, distributed among 4 treatment groups: NxV(vehicle), NxLos(Los), NxNOF(NOF), and NxLos/NOF(Los/NOF). Nxprerats exhibited marked albuminuria, hypertension, glomerulosclerosis, interstitial expansion, and macrophage infiltration, accompanied by abnormal glomerular, vascular, and interstitial COX-2 expression. ANG II appeared in interstitial cells, in contrast to S, in which ANG II was virtually confined to afferent arterioles. Intrarenal AT1R distribution shifted from mostly tubular in S to predominantly interstitial in Nxpre. All these changes were aggravated at 120 days and attenuated by Los and NOF monotherapies. Los/NOF treatment arrested renal structural injury and ANG II expression and reversed hypertension, albuminuria, and renal inflammation. In conclusion, abnormal expression of COX-2, ANG II, and AT1R may be key to development of renal injury in Nx. Concomitant COX-2 inhibition and AT1R blockade arrested renal injury and may represent a useful strategy in the treatment of chronic nephropathies.
- 1 January 2003
- Published by Elsevier in Kidney International
- Vol. 63 (1) , 209-216
Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes
- 1 January 2003
- Published by Elsevier in Kidney International
- Vol. 63 (1) , 209-216
Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes
- Open Access
- 1 December 2002
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 283 (6) , F1167-F1175
Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies
The incidence of progressive nephropathies and, consequently, the population suffering from end-stage renal disease have increased steadily in recent years, posing an ever-growing cost, in both human and financial terms, to society. There is mounting evidence that, in both immune-mediated and nonimmune-mediated chronic nephropathies, renal inflammatory events are key to the propagation and perpetuation of renal injury. Mycophenolate mofetil (MMF) is an antilymphocyte agent recently introduced in clinical practice for the prevention of allograft rejection. The present review discusses clinical and experimental evidence that the anti-inflammatory action of MMF can be advantageously used to arrest immune- and nonimmune-mediated progressive injury of native kidneys as well.
- 1 December 2002
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 283 (6) , F1167-F1175
Open AccessExperimental and clinical rationale for use of MMF in nontransplant progressive nephropathies
The incidence of progressive nephropathies and, consequently, the population suffering from end-stage renal disease have increased steadily in recent years, posing an ever-growing cost, in both human and financial terms, to society. There is mounting evidence that, in both immune-mediated and nonimmune-mediated chronic nephropathies, renal inflammatory events are key to the propagation and perpetuation of renal injury. Mycophenolate mofetil (MMF) is an antilymphocyte agent recently introduced in clinical practice for the prevention of allograft rejection. The present review discusses clinical and experimental evidence that the anti-inflammatory action of MMF can be advantageously used to arrest immune- and nonimmune-mediated progressive injury of native kidneys as well.
- 1 June 2002
- Vol. 20 (3) , S37-44
Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide.
There is mounting evidence that a number of inflammatory mechanisms play a crucial role in the pathogenesis of both immune- and non-immune-mediated glomerulopathies. These mechanisms include T lymphocyte activation, macrophage infiltration and the expression of several cytokines, growth factors and adhesion molecules. Inflammation may also be strongly influenced by three, until recently, unsuspected mediators: angiotensin II, cyclooxygenase derivatives and nitric oxide. Angiotensin II exerts several biological actions that are completely unrelated to its well-known haemodynamic effects, and can mediate cell proliferation, renal fibrosis and the synthesis of other proinflammatory compounds. Cyclooxygenase products have been long associated with non-renal inflammatory phenomena such as arthritis, and could mediate several steps of chronic renal inflammation. Although nitric oxide is generally regarded as a physiological vasodilator with irreplaceable homeostatic effects, it is possible that it participates in the pathogenesis of progressive nephropathies. Treatment with antagonists of these three compounds, alone or in combination, may represent a valuable therapeutic tool in the struggle to arrest or attenuate progressive renal disease.
- 1 June 2002
- Vol. 20 (3) , S37-44
Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide.
There is mounting evidence that a number of inflammatory mechanisms play a crucial role in the pathogenesis of both immune- and non-immune-mediated glomerulopathies. These mechanisms include T lymphocyte activation, macrophage infiltration and the expression of several cytokines, growth factors and adhesion molecules. Inflammation may also be strongly influenced by three, until recently, unsuspected mediators: angiotensin II, cyclooxygenase derivatives and nitric oxide. Angiotensin II exerts several biological actions that are completely unrelated to its well-known haemodynamic effects, and can mediate cell proliferation, renal fibrosis and the synthesis of other proinflammatory compounds. Cyclooxygenase products have been long associated with non-renal inflammatory phenomena such as arthritis, and could mediate several steps of chronic renal inflammation. Although nitric oxide is generally regarded as a physiological vasodilator with irreplaceable homeostatic effects, it is possible that it participates in the pathogenesis of progressive nephropathies. Treatment with antagonists of these three compounds, alone or in combination, may represent a valuable therapeutic tool in the struggle to arrest or attenuate progressive renal disease.
- 1 December 2000
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 279 (6) , F1060-F1066
Mechanisms of albuminuria in the chronic nitric oxide inhibition model
Chronic nitric oxide (NO) inhibition causes hypertension and renal injury. Concomitant salt overload promotes massive albuminuria. We investigated the mechanisms whereby these treatments impair glomerular permselectivity. Adult male Munich-Wistar rats received either a standard-salt (SS; 0.5% Na) or high-salt (HS; 3.1% Na) diet and either no treatment or the NO inhibitor Nω-nitro-l-arginine methyl ester (l-NAME). At 30 days, albuminuria was moderate, the density of fixed anionic sites at the glomerular basement membrane (GBM), estimated by cationic ferritin binding, declined by ∼35%, and the fractional clearance of 70-kDa neutral dextran (ϕ) rose moderately in rats receiving l-NAME and SS. Rats given l-NAME and HS exhibited massive albuminuria, whereas ϕ was nearly tripled. Depletion of GBM anionic sites was also seen in these rats. The GBM was thickened in bothl-NAME-treated groups. These abnormalities were largely reversed after cessation of treatments. These results indicate that chronic l-NAME treatment promotes reversible albuminuria by impairing both glomerular size and charge selectivity. These effects likely reflect functional rather than structural disruption of the glomerular wall.
- 1 December 2000
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 279 (6) , F1060-F1066
Mechanisms of albuminuria in the chronic nitric oxide inhibition model
Chronic nitric oxide (NO) inhibition causes hypertension and renal injury. Concomitant salt overload promotes massive albuminuria. We investigated the mechanisms whereby these treatments impair glomerular permselectivity. Adult male Munich-Wistar rats received either a standard-salt (SS; 0.5% Na) or high-salt (HS; 3.1% Na) diet and either no treatment or the NO inhibitor Nω-nitro-l-arginine methyl ester (l-NAME). At 30 days, albuminuria was moderate, the density of fixed anionic sites at the glomerular basement membrane (GBM), estimated by cationic ferritin binding, declined by ∼35%, and the fractional clearance of 70-kDa neutral dextran (ϕ) rose moderately in rats receiving l-NAME and SS. Rats given l-NAME and HS exhibited massive albuminuria, whereas ϕ was nearly tripled. Depletion of GBM anionic sites was also seen in these rats. The GBM was thickened in bothl-NAME-treated groups. These abnormalities were largely reversed after cessation of treatments. These results indicate that chronic l-NAME treatment promotes reversible albuminuria by impairing both glomerular size and charge selectivity. These effects likely reflect functional rather than structural disruption of the glomerular wall.